Global Human Growth Hormone Market Size & Outlook
Global human growth hormone market, 2018-2030 (US$M)
Related Markets
Global human growth hormone market highlights
- The global human growth hormone market generated a revenue of USD 6,321.8 million in 2023 and is expected to reach USD 14,279.5 million by 2030.
- The market is expected to grow at a CAGR (2024 - 2030) of 12.3% by 2030.
- In terms of segment, growth hormone deficiency accounted for a revenue of USD 3,093.3 million in 2023.
- Growth Hormone Deficiency is the most lucrative application segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2023.
- Country-wise, Sweden is expected to register the highest CAGR from 2024 to 2030.
Global data book summary
| Market revenue in 2023 | USD 6,321.8 million |
| Market revenue in 2030 | USD 14,279.5 million |
| Growth rate | 12.3% (CAGR from 2023 to 2030) |
| Largest segment | Growth hormone deficiency |
| Fastest growing segment | Growth Hormone Deficiency |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Other Applications, Growth Hormone Deficiency |
Other key industry trends
- In terms of revenue, the North America accounted for 42.2% of the global human growth hormone market in 2023.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, Sweden is the fastest growing regional market and is projected to reach USD 59.7 million by 2030.
Growth hormone deficiency was the largest segment with a revenue share of 48.93% in 2023. Horizon Databook has segmented the Global human growth hormone market based on turner syndrome, idiopathic short stature, prader-willi syndrome, small for gestational age, other applications, growth hormone deficiency covering the revenue growth of each sub-segment from 2018 to 2030.
Robust product pipeline and extensive R&D investments for the development of novel growth hormone therapies are expected to be major factors driving the market growth over the forecast period. In September 2018, Novo Nordisk presented Phase II clinical trial data of its investigational growth hormone therapy, Somapacitan, indicated for the treatment of pediatric growth hormone deficiency.
In May 2019, Ascendis Pharma A/S published results from the Phase III clinical trial of its Trans Con Growth Hormone (hGH), indicated for the pediatric growth hormone deficiency.
Similar, various key players including Teva Pharmaceutical Industries, Ltd., OPKO Health, Inc., Eli Lilly and Company, Ferring Pharmaceuticals, Sanofi S.A. and LG Life Sciences are involved in R&D activities for the development of novel human growth hormone therapies.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Human Growth Hormone Market Scope
Human Growth Hormone Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Global human growth hormone market size, by regions, 2018-2030 (US$M)
Top 10 countries: Human growth hormone market size, 2023 (US$M)
Global human growth hormone market share, by application, 2023 & 2030 (%, US$M)
Human growth hormone market: Opportunity assessment by country
Global human growth hormone market, by region, 2023 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
